Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC
Metrics: PDF 1161 views | HTML 3842 views | ?
Stefan Langhammer1 and Joachim Scheerer1
1 Life Science Consulting, Hirschweg, Burgwedel, Germany
Stefan Langhammer, email:
Keywords: NSCLC, targeted therapy, EGFR, angiogenesis
Received: December 16, 2016 Accepted: March 13, 2017 Published: March 29, 2017
In the light of current treatment developments for non-small cell lung cancer (NSCLC), the idea of a plastic cellular tumorigenic network bound by key paracrine signaling pathways mediating resistances to targeted therapies is brought forward. Based on a review of available preclinical and clinical data in NSCLC combinational approaches to address drivers of this network with marketed drugs are discussed. Five criteria for selecting drug combination regimens aiming at its disruption and thereby overcoming resistances are postulated.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.